Drug Trial Radar · NCT00238745
Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.
Last checked: Nov 20, 2026Latest source record: Dec 20, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
375
Actual
Start
Aug 2003
Primary completion
Not stated
Study completion Mar 2007
Sponsor
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 13, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Who can join
- Female only, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Dose-response in Japanese patients with postmenopausal osteoporosis.
Conditions
- Postmenopausal Osteoporosis
Interventions
BazedoxifeneDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bone mineral density of lumbar spine (L1-L4) at 2 years.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.